Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amarin Corporation plc - American Depositary Shares (NQ:AMRN)

15.16 +0.42 (+2.85%)
Streaming Delayed Price Updated: 11:19 AM EST, Feb 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 16,388
Open 14.72
Bid (Size) 15.10 (300)
Ask (Size) 15.25 (1,100)
Prev. Close 14.74
Today's Range 14.49 - 15.16
52wk Range 7.080 - 20.90
Shares Outstanding 407,265,944
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization
From Amarin Corporation plc
Via GlobeNewswire

Performance

YTD
+10.5%
+10.5%
1 Month
-2.3%
-2.3%
3 Month
-5.5%
-5.5%
6 Month
-6.2%
-6.2%
1 Year
+24.8%
+24.8%

More News

Read More
News headline image
Earnings Scheduled For October 29, 2025 ↗
Via Benzinga
News headline image
Earnings Outlook For Amarin Corp ↗
Via Benzinga
News headline image
Earnings Scheduled For July 30, 2025 ↗
Via Benzinga
News headline image
Earnings Scheduled For May 7, 2025 ↗
Via Benzinga
News headline image
Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities
From Amarin Corporation plc
Via GlobeNewswire
News headline image
New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Corp (NASDAQ:AMRN) Beats Q3 2025 Earnings and Revenue Estimates ↗
Via Chartmill
Topics Earnings
News headline image
Amarin Reports Third Quarter 2025 Financial Results
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Issues Statement Supporting FDA’s Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular Benefit
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin to Report Third Quarter 2025 Financial Results and Host Conference Call on October 29, 2025
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025
From Amarin Corporation plc
Via GlobeNewswire
News headline image
New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups
From Amarin Corporation plc
Via GlobeNewswire
News headline image
New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Reports Second Quarter 2025 Financial Results
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Shares Surge After $175M European Licensing Deal For Heart Drug VAZKEPA ↗
Via Benzinga
News headline image
Amarin Lands Massive European Commercialization Deal For Heart Drug Vazkepa, Stock Surges ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Via Benzinga
News headline image
Which stocks are gapping on Tuesday? ↗
Via Chartmill
News headline image
Amarin Announces Exclusive License and Supply Agreement with Recordati to Commercialize VAZKEPA® (Icosapent Ethyl) in Europe
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Reports First Quarter 2025 Financial Results
From Amarin Corporation plc
Via GlobeNewswire

Frequently Asked Questions

Is Amarin Corporation plc - American Depositary Shares publicly traded?
Yes, Amarin Corporation plc - American Depositary Shares is publicly traded.
What exchange does Amarin Corporation plc - American Depositary Shares trade on?
Amarin Corporation plc - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Amarin Corporation plc - American Depositary Shares?
The ticker symbol for Amarin Corporation plc - American Depositary Shares is AMRN on the Nasdaq Stock Market
What is the current price of Amarin Corporation plc - American Depositary Shares?
The current price of Amarin Corporation plc - American Depositary Shares is 15.16
When was Amarin Corporation plc - American Depositary Shares last traded?
The last trade of Amarin Corporation plc - American Depositary Shares was at 02/17/26 11:19 AM ET
What is the market capitalization of Amarin Corporation plc - American Depositary Shares?
The market capitalization of Amarin Corporation plc - American Depositary Shares is 6.17B
How many shares of Amarin Corporation plc - American Depositary Shares are outstanding?
Amarin Corporation plc - American Depositary Shares has 6B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.